Appointment dossier — Endometrial Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Endometrial Carcinoma
- Sacituzumab Govitecan — Animal evidence · 1 positive · PMID 40344963
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05542407 · Phase 1 — ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (United States)
- NCT07407959 — Screening and Staging of Benign vs Malignant Pelvic Abnormalities (United States)
- NCT06632431 — Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO) (Egypt)
- NCT05770102 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (United Kingdom)
- NCT06172478 · Phase 2 — A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (United States)
- NCT06330064 · Phase 2 — A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) (United States)
- NCT04300556 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (United States)
- NCT05103683 · Phase 1 — First in Human Study of TORL-1-23 in Participants With Advanced Cancer (United States)
- NCT06270706 · Phase 1 — A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors (United States)
- NCT07306559 · Phase 1 — A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) (United States)
- NCT06515613 · Phase 1 — A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors (United States)
- NCT05238922 · Phase 1 — Study of INCB123667 in Subjects With Advanced Solid Tumors (United States)
- NCT05610501 — Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. (Belgium)
- NCT05316935 · Phase 2 / Phase 3 — GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (China)
- NCT07054567 · Phase 2 — A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer (China)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
- NCT06040970 · Phase 1 / Phase 2 — Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer (United States)
- NCT04683653 · Phase 1 / Phase 2 — Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer (United States)
Most-relevant first: trials that name Endometrial Carcinoma, then broader trials you may still qualify for. 330 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT05542407), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?